Profile data is unavailable for this security.
About the company
Hinova Pharmaceuticals Inc is a China-based company primarily engaged in the research, development, production and commercialization of innovative drugs. The Company’s main products include the androgen receptor (AR) inhibitor deuterenzalutamide soft capsules (HC-1119), the oral protein degradation-targeting chimeric (PROTAC) drug HP518, the thyroid hormone β-receptor agonist (THR-β) agonist HP515, the urate transporter 1 inhibitor (URAT1) inhibitor HP501, the oral PROTAC drug HP568 and the bromodomain and extra terminal domain (BET) inhibitor HP560. The Company's drugs are primarily used to treat cancers such as prostate cancer, breast cancer and hematologic malignancies, as well as metabolic diseases such as hyperuricemia, non-alcoholic steatohepatitis (MASH), obesity and diabetes.
- Revenue in CNY (TTM)23.61m
- Net income in CNY-144.57m
- Incorporated2013
- Employees173.00
- LocationHinova Pharmaceuticals IncNo. 2 and 3, 4F, Building 1Rongyao Mansion, No. 5, Keyuan South RoCHENGDU 610041ChinaCHN
- Phone+86 2 885058465
- Fax+86 2 885058465
- Websitehttps://www.hinovapharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Xinjiang Bai Hua Cun Pharma Tech Co Ltd | 393.73m | 50.20m | 3.52bn | 731.00 | 70.08 | 4.44 | -- | 8.95 | 0.1307 | 0.1307 | 1.02 | 2.06 | 0.3503 | 1.94 | 1.88 | 538,619.70 | 4.47 | -4.60 | 6.16 | -6.38 | 51.82 | 24.75 | 12.75 | -16.33 | 1.81 | -- | 0.00 | -- | 4.46 | 8.04 | 219.75 | 3.82 | -0.975 | -- |
| Qingdao Vland Biotech INC | 1.39bn | 83.57m | 3.93bn | 1.57k | 47.18 | 2.21 | -- | 2.82 | 0.329 | 0.329 | 5.50 | 7.01 | 0.4585 | 3.89 | 3.65 | -- | 3.76 | 4.84 | 6.11 | 6.94 | 44.19 | 45.52 | 8.20 | 9.54 | 0.877 | -- | 0.2648 | 32.35 | 10.16 | 9.30 | -22.39 | -4.23 | -2.71 | -6.89 |
| Hinova Pharmaceuticals Inc | 23.61m | -144.57m | 4.56bn | 173.00 | -- | 4.14 | -- | 192.97 | -1.46 | -1.46 | 0.2384 | 11.12 | 0.0171 | 2.37 | 5.59 | 136,467.70 | -10.45 | -26.09 | -11.68 | -29.74 | 95.50 | -- | -612.36 | -78,863.60 | 6.90 | -- | 0.0883 | -- | -- | -38.67 | 32.18 | -- | 139.77 | -- |
| Shanghai Aladdin Biochemical Tech Co Ltd | 599.98m | 83.95m | 5.40bn | 652.00 | 65.35 | 5.06 | -- | 9.00 | 0.2485 | 0.2485 | 1.78 | 3.21 | 0.2785 | 0.4218 | 4.55 | 920,216.30 | 5.04 | 7.81 | 6.90 | 8.60 | 62.21 | 60.61 | 18.09 | 24.95 | 1.53 | 9.15 | 0.3541 | 48.33 | 32.44 | 20.55 | 15.07 | 9.17 | 41.61 | -- |
| Shouyao Holdings Co Ltd | 2.14m | -206.73m | 5.42bn | 178.00 | -- | 8.28 | -- | 2,529.30 | -1.39 | -1.39 | 0.0144 | 4.40 | 0.0025 | 0.0366 | 0.2625 | 12,033.88 | -23.67 | -32.53 | -27.20 | -36.25 | 95.74 | 99.43 | -9,651.03 | -3,370.01 | 6.42 | -- | 0.0044 | -- | -24.61 | -19.34 | -14.21 | -- | 49.71 | -- |
| Hangzhou Alltest Biotech Co Ltd | 881.63m | 294.76m | 5.45bn | 969.00 | 18.47 | 1.40 | -- | 6.19 | 3.72 | 3.72 | 11.12 | 49.21 | 0.2098 | 2.38 | 6.39 | 909,839.10 | 7.02 | 19.18 | 7.57 | 21.66 | 55.00 | 57.79 | 33.47 | 38.82 | 8.34 | -- | 0.0093 | 35.14 | 14.83 | 29.13 | 67.50 | 30.99 | 71.01 | -- |
| Bide Pharmatech Co Ltd | 1.27bn | 153.31m | 5.60bn | 738.00 | 35.04 | 2.79 | -- | 4.41 | 1.76 | 1.76 | 14.49 | 22.03 | 0.5167 | 0.8804 | 5.25 | 1,720,520.00 | 6.24 | 7.02 | 7.52 | 8.29 | 43.30 | 42.16 | 12.07 | 13.13 | 2.78 | -- | 0.1055 | 48.73 | 0.9298 | 34.69 | 7.17 | -- | 80.65 | -- |
Data as of Feb 06 2026. Currency figures normalised to Hinova Pharmaceuticals Inc's reporting currency: Chinese Yuan Renminbi CNY
36.56%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Penghua Fund Management Co., Ltd.as of 30 Jun 2025 | 5.11m | 22.58% |
| China Fund Management Co., Ltd.as of 30 Jun 2025 | 2.09m | 9.23% |
| Yinhua Fund Management Co., Ltd.as of 30 Jun 2025 | 615.54k | 2.72% |
| E Fund Management Co., Ltd.as of 30 Jun 2025 | 140.28k | 0.62% |
| CIB Fund Management Co., Ltd.as of 30 Jun 2025 | 80.58k | 0.36% |
| China Asset Management Co., Ltd.as of 30 Jun 2025 | 64.75k | 0.29% |
| First-Trust Fund Management Co., Ltd.as of 30 Jun 2025 | 54.22k | 0.24% |
| Lion Fund Management Co., Ltd.as of 30 Jun 2025 | 50.00k | 0.22% |
| China Southern Asset Management Co., Ltd.as of 30 Jun 2025 | 39.84k | 0.18% |
| Huatai-PineBridge Fund Management Co., Ltd.as of 30 Jun 2025 | 28.26k | 0.13% |
More ▼
Data from 30 Jun 2025 - 30 Nov 2025Source: FactSet Research Systems Inc.
